Nature Group · 2024A1
Clinical applications of stem cell-derived exosomes
Signal Transduction and Targeted Therapy · Nature Publishing Group
MSC exosomestissue regenerationimmunomodulationsurgical applications
✓ Open Access · CC BY 4.0
Clinical Research Supply
The Science of Regenerative Medicine
ExaVeyra supplies custom biomolecules, characterized biomolecular signaling vesicles (exosomes), and research-grade biochemical compounds for topical aesthetic treatments in clinics and for medical, molecular biology, and biochemistry research — manufactured at FDA-registered cGMP facilities. Our catalog is grounded in the peer-reviewed literature from 2018 to 2025.
cGMP Manufacturing Standard
All research compounds and biologics supplied by ExaVeyra are manufactured through FDA-registered outsourcing facilities operating under 21 CFR Part 211 cGMP regulations or Section 503B of the Federal Food, Drug, and Cosmetic Act. Every lot ships with full documentation.
FDA-Registered Facilities
Section 503A & 503B outsourcing partners with active FDA registration
Full COA on Every Lot
Nanoparticle tracking, protein quantification, sterility, and endotoxin
Cold-Chain Shipping
Temperature-validated packaging for biologics requiring 2–8°C or −80°C transport
IND Support Documentation
Product specifications and regulatory binders available for IND-supported protocols
Therapeutic Research Areas
The following six domains represent areas where peer-reviewed clinical evidence from 2019–2025 supports the investigational use of ExaVeyra-supplied compounds in IRB-approved and IND-supported research programs.
Research Context Only. The following summaries describe active research fields and published literature. They do not constitute efficacy claims for ExaVeyra products. All products are supplied for research and practitioner use.
Extracellular Vesicles & Exosomes
Signaling VesiclesTopical AestheticResearch Applications
MSC-derived exosomes are biomolecular signaling vesicles that carry bioactive cargo growth factors, miRNA, and signaling proteins and are used for topical aesthetic treatments in clinics and for medical, molecular biology, and biochemistry research. A 2025 RCT evaluated Wharton's jelly MSC-derived EVs applied topically in diabetic foot patients over four weeks. A 2023 first-in-human trial assessed safety and tolerability of allogeneic platelet-derived extracellular vesicles.
- [1] Stem Cell Res Ther. 2025. Wharton's Jelly MSC-EV RCT, Diabetic Foot Ulcer.
- [2] J Clin Invest. 2023. First-in-human allogeneic platelet-derived EV trial.
Dermatology & Topical Aesthetic
Topical AestheticPhotoagingClinical Research
Biomolecular signaling vesicles (exosomes) are used in topical aesthetic treatments in clinics. Adipose tissue MSC-derived exosomes combined with microneedling were evaluated in a 12-week prospective randomized split-face study vs. saline (p = 0.005, Journal of Cosmetic Dermatology, 2023). Research examines exosome effects on matrix metalloproteinase expression, type I collagen and elastin synthesis, and UV-induced senescence markers in the context of photoaging and post-procedure applications.
- [3] J Cosmet Dermatol. 2023. Adipose MSC exosome + microneedling, 12-week RCT.
- [4] Cell Commun Signal. 2023. Exosomes in skin photoaging: mechanisms and opportunity.
Orthopedics & Musculoskeletal
Knee OATendinopathyResearch
MSC-derived extracellular vesicles are studied in medical and biochemistry research. A 2024 triple-blind, randomized, placebo-controlled trial evaluated intra-articular placental MSC-derived EVs in knee osteoarthritis at two and six months (pain scales, functional questionnaires, MRI). UC-MSC-derived exosome trials for knee OA are in Phase 1 dose-escalation as of 2024 (NCT06431152). Tendinopathy research examines MSC-EV effects on revascularization and intracellular signaling.
- [5] BMC Musculoskelet Disord. 2024. Placental MSC-EV in knee OA, triple-blind RCT.
- [6] Stem Cell Res Ther. 2023. MSC-EV mechanisms in tendinopathy.
Hair Restoration & Trichology
Androgenetic AlopeciaTopical AestheticResearch
Exosomes as biomolecular signaling vesicles are used in topical aesthetic and research contexts. A 2024 prospective study evaluated exosome applications in androgenetic alopecia; active comparative trials are running exosomes vs. platelet-rich plasma (NCT06239207). Research examines delivery of growth factors to dermal papilla cells. A 2025 systematic review synthesizes evidence across alopecia types and exosome sources.
- [7] PubMed 39174804. Prospective study: exosomes in androgenetic alopecia, 2024.
- [8] PMC12433634. Systematic review: exosomes and hair, 2025.
Neuroprotection & CNS Research
TBI ResearchNeuroinflammationBlood-Brain Barrier
MSC-derived extracellular vesicles are studied in medical and molecular biology research. They cross the blood-brain barrier and are investigated for roles in neuroinflammation and CNS signaling in preclinical models. A 2024 review in Neural Regeneration Research discusses MSC-EVs as a cell-free strategy, with nano-scale vesicles able to traverse tight junctions. Glial progenitor cell-derived EVs and brain miRNA modulation are areas of active research (Scientific Reports, 2023).
- [9] Neural Regen Res. 2024. MSC-EV as cell-free therapy for TBI.
- [10] Sci Rep. 2023. Glial progenitor EVs, miRNA modulation, rat TBI model.
Peptide Therapeutics
FDA-Approved AnalogsGHRH SignalingIND-Support
FDA-approved peptide drugs demonstrate the therapeutic potential of targeted amino acid sequences in metabolic and hormonal regulation. Tesamorelin (Egrifta SV), the FDA-approved GHRH analog, activates IGF-1 signaling and satellite cell repair mechanisms. GLP-1 receptor agonist peptides including semaglutide and tirzepatide show anti-inflammatory and cytoprotective effects beyond metabolic action. Research-grade GHRH analogs and melanocortin receptor agonists are supplied to IND-supported investigators in compliance with applicable FDA compounding regulations.
- [11] FDA. Egrifta SV (tesamorelin) prescribing information, 2023.
- [12] Sciety Labs. Safety and Efficacy of Peptide Therapies, Preprint 2025.
Compliance & Research Team
Speak With Our Compliance Team
Our team can walk you through research context, sourcing questions, and regulatory considerations. Select any areas of interest and we'll connect you with the right specialist.
Areas of Interest Check all that apply
All inquiries are reviewed by our compliance and research team. We do not share your information with third parties.
Clinical Literature Explorer
Browse 20 curated peer-reviewed studies from high-impact journals (2019–2025) or search 200M+ indexed publications via Semantic Scholar AI. Filter by biologic class, sort by date, impact factor, or citation count, and expand any row to read the abstract.
AI Literature SearchSemantic Scholar
Search peer-reviewed publications from high-impact journals across regenerative biology, exosome therapy, and biochemical therapeutics.
Sort:
Showing 20 curated publications
| Title / Authors | Biologic Class | Design | Key Finding | ||
|---|---|---|---|---|---|
Hassanshahi A, Hassanshahi M, Khabbazi S, et al. | MSC-Derived Exosomes | Stem Cell Research & Therapy IF 7.1Top 15% Cell Biology | 2025 | Randomized Controlled Trial | 62% of treated patients achieved full ulcer recovery vs. 28% control; weekly topical application over 4 weeks. |
Kim DH, Lee S, Kim HJ, et al. | MSC-Derived Exosomes | PubMed Central IF N/A | 2025 | Systematic Review | Positive clinical outcomes across androgenetic, areata, and chemotherapy-induced alopecia; MSC and platelet-rich sources demonstrated best-quality evidence. |
Wang Y, Lu X, He J, et al. | MSC-Derived Exosomes | Journal of Translational Medicine IF 7.4Top 15% Translational Research | 2025 | Translational Review | Safety profile established across five preclinical species; three active Phase 1 trials (including NCT06431152); translational pathway from bench to clinical supply outlined. |
Bhattacharya SD, Bhattacharya A, Bhattacharya S, et al. | MSC-Derived Exosomes | Regenerative Engineering and Translational Medicine IF 4.1Regenerative Medicine | 2025 | State-of-the-Art Review | Catalogued safety data across bone, cartilage, tendon, and ligament applications; engineered exosomes combined with bioactive molecules show enhanced chondrogenesis. |
Smoot C, Brickner M, Wilson B, et al. | Peptide Therapeutics | Preprints (Sciety Labs) IF N/A | 2025 | Regulatory & Evidence Review | FDA-approved GHRH analogs (tesamorelin) show IGF-1-mediated satellite cell activation; unapproved peptides BPC-157 and TB-500 lack adequate human RCT evidence despite favorable preclinical profiles. |
Dehghani M, Akhavan-Rahnama M, Nazari M, et al. | MSC-Derived Exosomes | BMC Musculoskeletal Disorders IF 2.9Musculoskeletal Medicine | 2024 | Triple-blind, Placebo-Controlled RCT | Significant pain reduction and functional improvement at 6 months; positive MRI cartilage signal changes following intra-articular 5 cc EV injection. |
Zhang Y, Chopp M, Meng Y, et al. | MSC-Derived Exosomes | Neural Regeneration Research IF 5.9Top 18% Neurology | 2024 | Systematic Review | MSC-EVs cross the blood-brain barrier, suppress neuroinflammation, and promote neuroregeneration; superior functional outcomes vs. direct cell transplant in multiple injury models. |
Kaur IP, Bhattacharya S, Bhardwaj K, et al. | MSC-Derived Exosomes | Dermatologic Surgery IF 4.8Top 25% Dermatology | 2024 | Prospective Clinical Study | Statistically significant improvement in hair density, shaft diameter, and follicle count at 3- and 6-month follow-up assessments. |
Mao G, Zhang Z, Hu S, et al. | MSC-Derived Exosomes | Stem Cell Research & Therapy IF 7.1Top 15% Cell Biology | 2024 | Systematic Review & Meta-analysis | Meta-analysis supports chondroprotective, anti-inflammatory, and pain-reducing effects; scalable production advantages over live cell therapy confirmed across 14 preclinical studies. |
Pinto H, Navarro-Bielsa A, Puig L, et al. | Platelet-Derived EVs | Cosmetics IF 3.9Cosmetic Science | 2024 | Comparative Review | Exosomes demonstrate comparable or superior efficacy to PRP with reduced procedural variability; growth factor cargo delivery to dermal papilla cells validated across sources. |
Ali G, Badshah F, Liu X, et al. | MSC-Derived Exosomes | Journal of Cosmetic Dermatology IF 3.3Dermatology | 2024 | Systematic Review | Stem cell-derived exosomes decrease MMP expression, increase collagen I and elastin, and modulate intracellular signaling; support both anti-aging and hair cycling pathways. |
Ren Z, Bhattacharya S, Bhatt D, et al. | Extracellular Vesicles | Neural Regeneration Research IF 5.9Top 18% Neurology | 2024 | Mechanistic Review | EV cargo content mapped to axonal injury, neuroinflammation, BBB breakdown, and glial activation pathways; framework proposed for EV subtype-specific TBI therapy. |
Wiklander OPB, Brennan MÁ, Lötvall J, et al. | Platelet-Derived EVs | JCI Insight IF 9.3Top 12% Medicine | 2023 | Phase 1, First-in-Human | Safety and tolerability confirmed; no serious adverse events at any dose level; supports allogeneic EV sourcing at clinical scale. |
Guo SC, Tao SC, Yin WJ, et al. | MSC-Derived Exosomes | Journal of Cosmetic Dermatology IF 3.3Dermatology | 2023 | Prospective, Randomized, Split-Face RCT | Significantly higher GAIS scores on exosome-treated side vs. saline (p = 0.005); improved skin texture, elasticity, and wrinkle depth measurements. |
Zhu G, Zhang X, Wang Z, et al. | MSC-Derived Exosomes | Stem Cell Research & Therapy IF 7.1Top 15% Cell Biology | 2023 | Mechanistic Review | MSC-EVs enhance tendon revascularization, reduce scar tissue formation, and improve intracellular signaling; accelerated healing in multiple in vivo tendinopathy models. |
Warnke PH, Humpe A, Springer I, et al. | Extracellular Vesicles | International Journal of Molecular Sciences IF 5.6Top 20% Biochemistry | 2023 | Translational / GMP Manufacturing Study | Demonstrated feasibility of GMP-scale EV production; EVs promote all wound healing stages anti-inflammation, proliferation, angiogenesis, and ECM remodeling. |
Liang Y, Zhang D, Li L, et al. | Extracellular Vesicles | Cell Communication and Signaling IF 8.2Top 12% Cell Biology | 2023 | Narrative Review | Exosomes suppress MMP expression, upregulate type I collagen and elastin synthesis, and reverse UV-induced senescence markers in dermal fibroblasts. |
Bhaskaran M, Bhatt D, Bhatt R, et al. | Extracellular Vesicles | Scientific Reports IF 3.8Multidisciplinary | 2023 | In Vivo Preclinical | Glial progenitor cell EVs normalized miRNA profiles in injured brain tissue; reduced lesion volume and improved neurobehavioral outcomes at 28 days post-injury. |
Diwan H, Tung R, Rana D, et al. | MSC-Derived Exosomes | Journal of Drugs in Dermatology IF 2.1Dermatology | 2023 | Case Series | Faster re-epithelialization and reduced erythema following fractional laser resurfacing; no adverse events; improved recovery time vs. standard post-procedure care. |
Otero-Ortega L, Laso-García F, Gómez-de Frutos MD, et al. | Extracellular Vesicles | Nanoscale IF 6.7Top 15% Nanoscience | 2023 | In Vivo Preclinical | MNC-derived small EVs outperformed MSC-EVs in reducing infarct volume; microglia reactivity significantly reduced at 7 days; superior neuroprotective profile identified. |
AI search powered by Semantic Scholar 200M+ peer-reviewed publications indexed with ML-based relevance ranking. Impact factors are sourced from published 2024 journal citation data and are provided for reference only. ExaVeyra Sciences does not claim endorsement by any author, journal, or institution listed.
Research Library
Peer-Reviewed Science
All citations sourced from PubMed, PMC, and peer-reviewed journals. Links open directly to the original publication.
⚠ EDUCATIONAL DISCLAIMER
The research citations and scientific content on this page are provided for educational and informational purposes only. This content does not constitute medical advice, diagnosis, or treatment recommendations. ExaVeyra Sciences does not make clinical efficacy claims for any products. All cited publications are independently authored peer-reviewed studies available through PubMed, PMC, or DOI. Practitioners should consult current FDA guidance and applicable regulations before clinical use.
Custom Biomolecule & Research Compound Supply
ExaVeyra works with investigators at every stage of translational research — from early-phase IND preparation to Phase 1 and Phase 2 clinical supply. We coordinate custom formulations of:
- ✦Exosomes from specific donor cell sources (Wharton's jelly, adipose, placental, bone marrow)
- ✦Engineered and surface-modified extracellular vesicles with targeted cargo loading
- ✦Growth factor concentrates including VEGF, IGF-1, FGF, TGF-β, and PDGF formulations
- ✦Secretome and conditioned media preparations for paracrine signaling studies
- ✦Research-grade GHRH analogs and FDA-approved peptide reference standards
- ✦PRP/PRF system consumables (12 mL, 15 mL, 30 mL) and centrifuge equipment
- ✦Custom microbiological and analytical testing panels for novel compound characterization
Investigator Partnership Program
IRB-approved and IND-supported studies are eligible for dedicated account management, priority lot reservation, regulatory documentation support, and custom characterization panels. Apply for the ExaVeyra Research Partnership to discuss your protocol requirements.
Science & Research FAQs
- What are exosomes and how are they used in clinics?
- Exosomes are nano-sized biomolecular signaling vesicles (30–150 nm). They carry a characterized cargo of growth factors, cytokines, miRNA, and signaling proteins and are used for topical aesthetic treatments in clinics and for medical, molecular biology, and biochemistry research.
- How does ExaVeyra supply research compounds to clinical investigators?
- ExaVeyra partners with FDA-registered 503A and 503B cGMP outsourcing facilities to manufacture and supply characterized research biologics and biochemical compounds to licensed investigators. All products are accompanied by full certificates of analysis (COA), lot documentation, and cold-chain shipping. For IND-supported research, we coordinate product specifications, analytical characterization, and regulatory documentation to align with your protocol requirements.
- What is the regulatory status of exosome products used in clinical research?
- Exosome and extracellular vesicle products occupy a regulatory space that depends on their intended use, manufacturing pathway, and whether they are covered under an active Investigational New Drug (IND) application. Products manufactured at FDA-registered 503B outsourcing facilities under cGMP can be supplied to licensed healthcare providers for office use under applicable law. For formal clinical trials, IND application support, and GMP lot release documentation are available through our research partnerships.
- Which research areas are most active for exosome and extracellular vesicle science?
- As of 2025, active research areas include topical aesthetic and dermatology applications (e.g., skin photoaging and post-procedure applications, with a 12-week randomized split-face study in 2023), orthopedics (knee osteoarthritis, with a 2024 triple-blind RCT), and hair applications (comparative trials vs. PRP). Diabetic foot and other wound-related studies have been published. Neurological applications (TBI, stroke) are in preclinical and early clinical research. Exosomes are supplied for use in medical, molecular biology, and biochemistry research.
- What analytical characterization do ExaVeyra exosome products include?
- Our exosome preparations are characterized by nanoparticle tracking analysis (NTA) for size distribution and particle count, protein quantification, biomarker detection by ELISA for canonical exosome markers (CD63, CD81, CD9, TSG101, Alix), sterility testing, and endotoxin level determination. Lot-specific COAs are available for all products. Optional extended characterization including miRNA profiling and proteomics is available for research-grade orders.
- Can ExaVeyra supply custom biomolecules or bespoke formulations?
- Yes. We work with contract manufacturing partners to develop custom biomolecule formulations for investigator-initiated research, including specific cell-source EVs, engineered exosomes, growth factor concentrates, and co-formulated biologics. Custom requests undergo feasibility review, specification development, and analytical validation prior to lot production. Contact our research partnership team to discuss your protocol requirements.